Ultime notizie per SQZ Biotechnologies (OTC:SQZB) Azioni

SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.

SQZ BIOTECHNOLOGIES CO by SQZ Biotechnologies Company

SQZ Biotechnologies Co

Navios Maritime Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMM#NYSE">NMM</a>) reported quarterly earnings of $3.11 per share. The company reported $332.50 million in sales this quarter. This is a 1.60 percent increase over sales of $327.25 million the same period last year.

Earnings

News

Navios Maritime Partners Q4 2024 GAAP EPS $3.11, Sales $332.50M Up From $327.25M YoY

Earnings Beats

CEVA

CEVA Q4 2024 Adj. EPS $0.11, Inline, Sales $29.223M Beat $27.558M Estimate

Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.72 by 2.78 percent. This is a 39.62 percent increase over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $1.891 billion which beat the analyst consensus estimate of $1.879 billion by 0.66 percent. This is a 9.24 percent increase over sales of $1.731 billion the same period last year.

Howmet Aerospace Q4 2024 Adj. EPS $0.74 Beats $0.72 Estimate, Sales $1.891B Beat $1.879B Estimate

CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) is looking for FY2025 Adj EPS of $5.80-$6.10 vs $6.03 analyst estimate..

Guidance

CBRE

CBRE Group Sees FY2025 Core EPS EPS of $5.80-$6.10 vs $6.03 Est

Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.70) by 12.86 percent. This is a 56.59 percent increase over losses of $(1.82) per share from the same period last year. The company reported quarterly sales of $146.37 million which beat the analyst consensus estimate of $145.84 million by 0.36 percent. This is a 103.41 percent increase over sales of $71.96 million the same period last year.

BPMC

Blueprint Medicines Q4 2024 GAAP EPS $(0.79) Misses $(0.70) Estimate, Sales $146.37M Beat $145.84M Estimate

CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) reported quarterly earnings of $2.32 per share which beat the analyst consensus estimate of $2.22 by 4.5 percent. This is a 68.12 percent increase over earnings of $1.38 per share from the same period last year. The company reported quarterly sales of $10.40 billion which beat the analyst consensus estimate of $10.29 billion by 1.16 percent. This is a 16.25 percent increase over sales of $8.95 billion the same period last year.

CBRE Group Q4 Core EPS $2.32 Beats $2.22 Estimate, Sales $10.40B Beat $10.29B Estimate

Fiscal Year 2025 Financial Outlook
Bruker expects FY 2025 revenues of $3.47 to $3.54 billion, compared to FY 2024 revenues of $3.37 billion, with 3% to 5% year-over-year reported revenue growth, including:
<ul>
<li>CER revenue growth of 5% to 7%</li>
<li>Organic revenue growth of 3% to 4%</li>
<li>M&amp;A revenue growth contribution of 2% to 3%</li>
<li>Foreign currency translation headwind of approximately 2%</li>
</ul>
Bruker expects FY 2025 non-GAAP EPS of $2.67 to $2.72, compared to FY 2024 non-GAAP EPS of $2.41, an increase of 11% to 13% year-over-year, with CER non-GAAP EPS growth of 14% to 16%.
Bruker's FY 2025 revenue and non-GAAP EPS guidance is based on foreign currency exchange rates as of December 31, 2024.

BRKR

Bruker FY2025 Outlook: Adj EPS $2.67-$2.72 vs $2.67 Estimate; Sales $3.470B-$3.540B vs $3.57B Estimate

The dividend is payable March 6, 2025, to shareholders of record as of February 24, 2025.

Dividends

Penske Automotive Increases Quarterly Dividend By 2.5% From $1.19 To $1.22 Per Share

Canaccord Genuity analyst David Hynes maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and raises the price target from $710 to $900.

Price Target

Analyst Ratings

HUBS

Canaccord Genuity Maintains Buy on HubSpot, Raises Price Target to $900

Earnings Misses

ATUS

Altice USA Q4 2024 GAAP EPS $(0.12) Misses $0.04 Estimate, Sales $2.235B Miss $2.240B Estimate

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.34 by 4.48 percent. This is a 12.9 percent increase over earnings of $1.24 per share from the same period last year. The company reported quarterly sales of $2.32 billion which beat the analyst consensus estimate of $2.30 billion by 0.74 percent. This is a 4.70 percent increase over sales of $2.21 billion the same period last year.

Zoetis Q4 2024 Adj EPS $1.40 Beats $1.34 Estimate, Sales $2.32B Beat $2.30B Estimate

Hanesbrands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) reported quarterly adjusted earnings of $0.17 per share which beat the analyst consensus estimate of $0.14 by 21.43 percent. This is a 466.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $888.47 million which missed the analyst consensus estimate of $950.27 million by 6.50 percent. This is a 31.50 percent decrease over sales of $1.30 billion the same period last year.

Hanesbrands Q4 Adj $0.17 Beats $0.14 Estimate, Sales $888.47M Miss $950.27M Estimate

Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) reported quarterly earnings of $0.10 per share which met the analyst consensus estimate. This is a 9.09 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $109.000 million which beat the analyst consensus estimate of $107.183 million by 1.70 percent. This is a 17.19 percent increase over sales of $93.013 million the same period last year.

CLBT

Cellebrite DI Q4 2024 Adj. EPS $0.10, Inline, Sales $109.000M Beat $107.183M Estimate

Moody's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) reported quarterly earnings of $2.61 per share which beat the analyst consensus estimate of $2.59 by 0.77 percent. This is a 19.18 percent increase over earnings of $2.19 per share from the same period last year. The company reported quarterly sales of $1.67 billion which missed the analyst consensus estimate of $1.70 billion by 1.82 percent. This is a 12.97 percent increase over sales of $1.48 billion the same period last year.

Moody's Q4 2024 Adj EPS $2.61 Beats $2.59 Estimate, Sales $1.67B Miss $1.70B Estimate

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.74 by 2.7 percent. This is a 8.57 percent increase over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $979.60 million which beat the analyst consensus estimate of $966.35 million by 1.37 percent. This is a 14.64 percent increase over sales of $854.50 million the same period last year.

Bruker Q4 2024 Adj EPS $0.76 Beats $0.74 Estimate, Sales $979.60M Beat $966.35M Estimate

WIIM

Barclays shares are trading lower following a Q4 EPS miss.

CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.72 by 11.11 percent. This is a 1.23 percent decrease over earnings of $0.81 per share from the same period last year. The company reported quarterly sales of $314.40 million which beat the analyst consensus estimate of $301.31 million by 4.35 percent. This is a 40.92 percent increase over sales of $223.10 million the same period last year.

CYBR

CyberArk Software Q4 2024 Adj EPS $0.80 Beats $0.72 Estimate, Sales $314.40M Beat $301.31M Estimate

Sonic Automotive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Sonic Automotive, presenting an average target of $80.5, a high estimate of $100.00, and a low estimate of $74.00. This current average reflects an increase of 8.3% from the previous average price target of $74.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1739448053_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Sonic Automotive. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Glenn Chin</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$74.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sonic Automotive. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Sonic Automotive compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Sonic Automotive's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sonic Automotive's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SAH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sonic Automotive analyst ratings.</a>
<h2>Delving into Sonic Automotive's Background</h2>
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 108 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 25 EchoPark used-vehicle stores, 16 collision centers, and 13 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 58% of new-vehicle revenue. BMW is the largest brand at about 25%. 2023's revenue was $14.4 billion, with EchoPark's portion totaling $2.4 billion. Sonic bought RFJ Auto in December 2021, which added $3.2 billion in sales.
<h3>Sonic Automotive's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Sonic Automotive's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -4.17% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Sonic Automotive's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.13%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sonic Automotive's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.28%, the company showcases efficient use of assets and strong financial health.
Debt Management: Sonic Automotive's debt-to-equity ratio is below the industry average at 4.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Sonic Automotive Stock

General

SHOO

Steve Madden Agreed To Acquire Uk-based Kurt Geiger From A Group Led By International Private Equity Firm Cinven For An Enterprise Value Of Approximately £289M In Cash

Cryptocurrency experts have warned against the use of double-leveraged Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) exchange-traded funds, emphasizing that these are designed for short-term trading strategies due to their daily rebalancing and inherent volatility. While the long-term investors risk significant losses.
What Happened: The double-leveraged ETFs tracking Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), formerly MicroStrategy, have raised concerns among cryptocurrency experts. The firm now known as just &#8216;Strategy&#8217; is a Michael Saylor-led company heavily invested in Bitcoin.
While these ETFs, like T-Rex 2X Long MSTR Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MSTU#BATS">MSTU</a>) launched in September, and Defiance Daily Target 2x Long MSTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTX#NASDAQ">MSTX</a>) launched in August, promise amplified daily returns, experts warn they are unsuitable for long-term investment strategies.
&#8220;Leveraged ETFs such as MSTU and MSTX offer multiples of the daily performance of the underlying stock, MicroStrategy Inc,&#8221; Srinivas L, MD &amp; CEO of 9Point Capital, told <a href="https://pro.benzinga.com/dashboard">Benzinga</a>.
&#8220;While the ETFs aim to double the daily return, they also double the potential loss. With the inherent volatility of Bitcoin, the doubling can lead to wild fluctuations in value.&#8221;
A key concern highlighted by experts is the impact of daily rebalancing, a mechanism inherent in leveraged ETFs.
&#8220;They're designed for short-term strategies, not long-term holding, as daily rebalancing can erode returns over time, especially in volatile markets,&#8221; says Thangapandi, CEO and Founder of Koinpark.
This daily rebalancing can lead to a phenomenon known as &#8220;value decay,&#8221; where the ETF&#8217;s long-term performance deviates significantly from the expected multiple of the underlying asset&#8217;s cumulative return, explains Srinivas L.
Sathvik Vishwanath, Co-founder and CEO of Unocoin, reinforces this point, stating, &#8220;Leveraged plays on BTC, or in this case, BTC-exposed companies like Strategy, are inherently high-risk.&#8221; These are best suited for &#8220;experienced traders rather than long-term investors.&#8221;
He emphasizes that these ETFs are designed for short-term trading and not holding and that their long-term returns often don&#8217;t match expected multiples, &#8220;due to daily rebalancing.&#8221;
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43683299/cisco-systems-lands-700m-ai-gold-rush-amid-increased-appetite-from-tech-giants-build-more-and-we-will-buy-more-customers-tell-ceo">Cisco Systems Lands $700M AI Gold Rush Amid Increased Appetite From Tech Giants: &#8216;Build More And We Will Buy More&#8217;</a>
Why It Matters: MSTU and MSTX have shown significant <a href="https://www.benzinga.com/24/12/42667093/microstrategy-etfs-face-tracking-error-because-of-volatility-here-are-the-potential-risks-investors-face">tracking errors in the past</a>, likely due to the company&#8217;s volatile swaps and options exposure.
These ETFs have on occasion deviated substantially from their intended 2x daily performance, as seen during the price swings in November 2024. It has exceeded or fallen short of expected movements based on Strategy&#8217;s stock price. These swings pose an increased risk for investors.
Strategy is the only publicly listed company holding the highest Bitcoin reserves, representing 2.28% of the total 21 million supply. According <a href="https://treasuries.bitbo.io/#public">to</a> BiTBO, MSTR held 478,740 coins, valued at $45.971 billion, as of Feb. 12, 2025.
See Also: <a href="https://www.benzinga.com/24/12/42667093/microstrategy-etfs-face-tracking-error-because-of-volatility-here-are-the-potential-risks-investors-face">Strategy ETFs Face Tracking Error Because Of Volatility: Here Are The Potential Risks Investors Face</a>
Price Action: Strategy rose by 2.30% to $326.82 apiece on Wednesday and advanced further by 0.44% in after-hours. The exchange-traded fund tracking the Nasdaq 100 index, Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose by 0.059%.
MSTR shares have gained 8.94% on a year-to-date basis, whereas it was down by 376.41% over the last year.
The average price target among 14 <a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">analysts tracked by Benzinga</a> is $494.93 with a ‘Buy' rating. The estimates range from $140 to $690 apiece. Recent ratings from Barclays, Keefe, Bruyette &amp; Woods, and Maxim Group suggest a $493.67 target, implying a potential upside of 50.39%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/MSTR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="380" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13020508/MSTR-ANR-Latest-1024x380.png" alt="" class="wp-image-780320" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13020508/MSTR-ANR-Latest-1024x380.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13020508/MSTR-ANR-Latest-300x111.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13020508/MSTR-ANR-Latest-768x285.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13020508/MSTR-ANR-Latest.png 1063w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43650247/marriotts-digital-penetration-hits-historic-highs-as-bonvoy-app-downloads-soar-adding-31-million-new-members-ceo-says-transformation-enhancing-the-customer-experience" target="_blank" rel="noreferrer noopener">Marriott's Digital Penetration Hits ‘Historic Highs' As Bonvoy App Downloads Soar Adding 31 Million New Members</a></li>
</ul>
Photo courtesy: Strategy

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Market Summary

Markets

ETFs

$BTC

MSTR

ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF

Comments

SQZ Biotechnologies

Notizie

Ultime notizie per SQZ Biotechnologies (OTC:SQZB) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO